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Background
Tuberculosis (TB) kills more people than any other infection and new diagnostic tests to identify active cases are urgently
required. We aimed to discover and verify novel markers for TB in non-depleted plasma.
Methods
We applied an optimised quantitative proteomics discovery methodology based on multidimensional and orthogonal liquid
chromatographic separation hyphenated with high-resolution mass spectrometry (q3D LC-MS) to study non-depleted
plasma of 11 patients with active TB compared to 10 healthy control donors. Prioritised candidates were verified in an
independent UK-based (n=118) and a South African cohorts (n=203).
Results
We generated the most comprehensive TB plasma proteome to date, profiling 5022 proteins spanning 11 orders-of-
magnitude concentration range with diverse biochemical and molecular properties. We further analysed the
predominantly low molecular weight sub-proteome; identifying 46 proteins with significantly increased and 90 with
decreased abundance (peptide FDR ≤1%, q-value ≤0.05). Biological network analysis showed regulation of new
pathways involving lipid and organophosphate ester transport. Verification was performed for novel candidate biomarkers
(CFHR5, ILF2) in two independent cohorts. These proteins were elevated in both TB and other respiratory diseases
(ORD). Receiver-operating-characteristics analyses using a 5-protein panel (CFHR5, LRG1, CRP, LBP and SAA1) […]
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Abstract 58 
 59 
Background 60 
Tuberculosis (TB) kills more people than any other infection and new diagnostic tests to identify 61 
active cases are urgently required. We aimed to discover and verify novel markers for TB in non-62 
depleted plasma.  63 
 64 
Methods 65 
We applied an optimised quantitative proteomics discovery methodology based on multidimensional 66 
and orthogonal liquid chromatographic separation hyphenated with high-resolution mass spectrometry 67 
(q3D LC-MS) to study non-depleted plasma of 11 patients with active TB compared to 10 healthy 68 
control donors. Prioritised candidates were verified in an independent UK-based (n=118) and a South 69 
African cohorts (n=203).  70 
 71 
Results 72 
We generated the most comprehensive TB plasma proteome to date, profiling 5022 proteins spanning 73 
11 orders-of-magnitude concentration range with diverse biochemical and molecular properties. We 74 
further analysed the predominantly low molecular weight sub-proteome; identifying 46 proteins with 75 
significantly increased and 90 with decreased abundance (peptide false discovery rate, FDR ≤1%, q-76 
value ≤0.05). Biological network analysis showed regulation of new pathways involving lipid and 77 
organophosphate ester transport. Verification was performed for novel candidate biomarkers (CFHR5, 78 
ILF2) in two independent cohorts.  These proteins were elevated in both TB and other respiratory 79 
diseases (ORD).  Receiver-operating-characteristics analyses using a 5-protein panel (CFHR5, LRG1, 80 
CRP, LBP and SAA1) exhibited discriminatory power in distinguishing between TB and ORD (AUC 81 
=0.81).   82 
 83 
Conclusions 84 
We report the most comprehensive TB plasma proteome to date, identifying numerous novel markers 85 
with verification in two independent cohorts, which led to a 5-protein biosignature with potential to 86 
improve TB diagnosis.  With further development, these biomarkers have potential as a diagnostic 87 
triage test.  88 
 89 
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Introduction 94 
The tuberculosis (TB) pandemic continues relentlessly, killing more humans than any other infectious 95 
disease, and progress is lagging behind other major diseases such as HIV and malaria (1). A 96 
fundamental issue with controlling the global pandemic is the inadequacy of current diagnostic tests 97 
for TB, which have multiple limitations such as insufficient sensitivity, high cost and reliance on 98 
laboratory infrastructure (2, 3). The World Health Organisation has defined the characteristics of an 99 
optimal TB diagnostic, including low-cost, use of a non-sputum sample, high sensitivity and 100 
specificity, as well as stability at extremes of temperature and humidity, and may include both rule-in 101 
and rule-out tests (4). However, development of a point-of-care test suitable for resource-limited 102 
settings faces multiple challenges in the pathway from discovery to validation and implementation, 103 
such as translation between platforms, application across different populations and the disease 104 
heterogeneity of TB. 105 
Proteins have been proposed as viable diagnostic candidates given their phenotypic relevance and 106 
stability under specified conditions. Blood plasma contains a wide spectrum of proteins that may 107 
serve as biological signatures of physiological status during homeostasis or its perturbation (5). For 108 
example, the plasma matrix encompasses tissue leakage proteins, thus providing systemic and 109 
organotypic insight about specific immunopathologic features such as lung tissue destruction relevant 110 
to active TB (6, 7).  Furthermore, plasma protein signatures are highly amenable for translation to 111 
rapid test devices and this technology is rapidly evolving, including colorimetric gold nanoparticles 112 
on paper-based devices, label-free biosensors and nanofluidic disposable chips (8, 9). Extensive 113 
proteomic discovery research has been conducted in TB. Although this has identified novel diagnostic 114 
markers for the active disease (10-16) and progression from latent disease (17), an optimal diagnostic 115 
panel has yet to be defined (18). Other analytes, such as matrix degradation products, have been found 116 
by a hypothesis-driven approach (7, 19), but conversely have not been identified by mass 117 
spectrometry based strategies.  This implies that improved discovery strategies are required to 118 
increase the plasma proteome coverage, thus improving the prospect in capturing novel protein 119 
markers with potential clinical utility. 120 
Current limitations to mainstream serum or plasma proteomics pipelines partly stems from the 121 
predominance in protein mass (>95%) of the top 20 most abundant proteins. These high abundant 122 
proteins either mask the presence of or are non-covalently bound to lower abundant proteins with 123 
potential clinical relevance. In an effort to overcome this limitation, an initial serum/plasma depletion 124 
step to remove such high abundance proteins is typically employed prior to the mass spectrometry-125 
based analysis. This plasma proteome analysis strategy has been used in samples from patients with 126 
TB (11, 13, 20-24).  However, this approach will result in the inadvertent loss of a wide spectrum of 127 
physiologically important proteins including those typically encountered in lipid microvesicles such 128 
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as exosomes, proteases and their cleavage products, and native peptides such as hormones (25, 26). 129 
Consequently, an alternative methodological approach has been optimised, wherein the entire 130 
repertoire of secreted and exosome-enriched proteins, including the high-abundant carrier and 131 
immunoglobulin proteins, and their derivative proteotypic peptides are subjected to multi-dimensional 132 
or orthogonal liquid chromatographic separation combined with high-definition mass spectrometry 133 
analysis (Figure 1) (27-29). The present study optimised critical aspects of this methodology to 134 
generate a highly comprehensive plasma proteome coverage to capture novel biomarkers in active 135 
TB. 136 
 137 
Results 138 
Proteomic analysis of non-depleted plasma identifies numerous modulated proteins in TB 139 
For each sample, four protein segments were generated from plasma by high-performance size 140 
exclusion chromatography (HP-SEC) partitioning under highly chaotropic mobile phase conditions. 141 
Then, each HP-SEC segment was subjected to downstream 2D LC-MS analysis to achieve a 142 
comprehensive profile of the non-depleted plasma proteome (Supplementary figure 1). The HP-SEC 143 
fractionation traces were highly reproducible (Supplementary figure 2).  All four segments from one 144 
set of seven plasma samples, comprising four samples from active TB patients, three from healthy 145 
donors and one master pool (Set A, Supplementary table 1) were profiled to generate an exploratory 146 
in-depth plasma proteome in TB (Figure 2). Samples included in this first stage were obtained from 147 
donors from South Africa and Peru. The samples from Peru were collected prospectively to match 148 
BMI and age of the donors from South Africa (Supplementary table 1).  A total of 5022 non-149 
redundant proteins (peptide FDR ≤5%) were identified from which 3577 were quantified across all 8 150 
samples. Only quantified proteins profiled at a strict 1% FDR were subjected to further bioinformatic 151 
and statistical analysis. Proteins profiled in the sub-proteome contained in segment four presented the 152 
widest distribution of molecular weight raging from 5KDa to 630KDa (Figure 2A). A total of 53% of 153 
the quantified proteins had reported circulating levels in the literature or the human plasma dataset 154 
(integrated) from the reference PaxDb4.1 protein abundance database (30, 31). Based on these reported 155 
circulating levels, the plasma proteomic profile covered abundance levels of 11 orders of magnitude 156 
(Figure 2B) representing classical, tissue-leakage and signalling proteins (32). Furthermore, 905 157 
profiled proteins were annotated as exosome-, microvesicle- or microparticle-derived proteins (33). 158 
The actual abundance dynamic range is expected to be larger, as the LC-MS signal intensity observed 159 
for many proteins with unknown native concentration levels is below that of proteins with the lowest 160 
previously reported concentrations. 161 
Principal component analysis (PCA) demonstrated that this plasma proteome could distinguish 162 
between controls and active TB patients (Figure 2C). Overall, 62% of the variance was explained by 163 
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PC1 and PC2. The master pool was a combination of plasma from healthy control and TB patients, 164 
and clustered in the centre of control and diseased groups. One TB patient profile (reporter ion at m/z 165 
121) clustered with the control group, and review of the clinical data showed that although the 166 
Mycobacterium tuberculosis (Mtb) sputum culture was positive, the plasma CRP level was normal 167 
and the chest X-ray showed no consolidation, suggesting very early disease, in contrast to all other 168 
patients who had lung inflammation. This demonstrates that proteomic profiling reflects disease 169 
heterogeneity that is consistent with clinical features.  170 
 171 
Similar to the PCA, Spearman correlation showed clustering between TB and controls, but with 172 
reporter ion at m/z 121 clustering with controls (Figure 2D). Defined patterns of protein expression 173 
associated to the disease status were observed in two clusters. Cluster blue includes proteins with 174 
reduced abundance in the TB group while cluster magenta contains proteins with increased abundance 175 
in the TB group. Gene ontology enrichment analysis indicated regulation of immune response to 176 
external stimulus mainly through the innate response, including the complement pathway and 177 
phagocytosis.  178 
 179 
Recently, analytical models such as Linear Models for Microarray Data (LIMMA) have been 180 
translated to proteomic datasets from large-scale gene expression data (34). Empirical Bayes 181 
approaches have been proven to be particularly powerful with small sample numbers by using the full 182 
datasets to reduce observed sample variances towards an estimate while allowing for variance 183 
distribution (35-37). This statistical approach results in a more realistic distribution of biological 184 
variances compared to other methods. Furthermore, LIMMA offered the best statistical properties 185 
when compared to generalised linear model (GLM) and mixed models in the context of multiplexed 186 
isobaric quantitative proteomics (34). Statistical assessment of differential expression showed 119 187 
proteins significantly modulated (nominal p-value ≤ 0.05) (Supplementary table 2).  However, after 188 
FDR correction for multiple comparisons, no significant differences were retained. Therefore, we 189 
increased the sample size to identify TB biomarker proteins with high confidence.  190 
 191 
In-depth analysis of segment 4 identifies multiple new TB biomarkers 192 
Robust statistics are crucial at the discovery stage of biomarker identification to increase chances of 193 
later validation. Considering that HP-SEC segment 4 captured the most diverse range of protein 194 
molecular weight (Figure 2A), we interrogated this segment further to increase statistical power. 195 
Reported simulations for statistical power in proteomic studies, including power curves estimated for 196 
iTRAQ relative ratios (37), predict that a minimum of 9 biological or clinical replicate samples per 197 
group are needed to achieve a statistical power of 0.9 when an effect size of 1.5 is considered (37, 38).  198 
Therefore, 10 healthy control and 11 active TB plasma samples were analysed. These samples were 199 
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randomly allocated into three iTRAQ experiments (Supplementary figure 2A) and analysed as three 200 
independent mass spectrometry (MS) experiments. A maximum of 1,248 proteins were quantified at 201 
1% FDR and 426 proteins were common to the three MS runs (Supplementary figure 2B). The overall 202 
relative protein expression variation was evaluated using the common proteins profiled across the 203 
three independent iTRAQ experiments. The relative standard deviation (RSD) was >25, which 204 
accounts for the combined technical and biological variation (Supplementary figure 2C). Using an 205 
alternative approach to estimate the mean-variance relationship in the data, the locally weighted 206 
regression (LOWESS) trend was calculated using the function voom (39) from the limma R package, 207 
analysing the same group of proteins (Supplementary figure 2D). The square-root-standard-deviation, 208 
sqrt (SD), was >1.4 and the LOWESS voom trend indicates a degree of heteroscedasticity in the data, 209 
where greater log2 relative expression values were related to higher variation. The range of RSD and 210 
sqrt(SD) estimated across these three multidimensional experiments indicates a good overall method 211 
performance.   212 
The datasets generated were inspected to evaluate batch effects and data distribution. Sixty percent of 213 
the variance was explained by the batch (Supplementary figure 4A). The group effect was then 214 
distinguishable when considering dimensions PC2 and PC3 (~17% variance, Supplementary figure 215 
4B). Batch effect correction was performed using normalisation to the master pool or by ComBat (40) 216 
(Supplementary figure 4C and 4D, respectively), with ComBat providing the best reduction of batch 217 
effects. Statistical assessment of significant differential protein expression using LIMMA revealed 218 
136 proteins significantly modulated (q-value ≤0.05; Supplementary table 3). Proteins with 219 
significantly increased and reduced abundance were identified in patients with active TB infection 220 
(Figure 3A). In addition to the identification of proteins known to be regulated during the course of 221 
the active TB immunopathology, such as CRP, SAA, S100A8, RBP4, MMP14 and diverse 222 
apolipoproteins, completely novel proteins were found, such as DLG4, SFTPB, CFHR5 and SPP2.  223 
Further data mining of the output from segment 4 was performed to interpret biologically relevant 224 
patterns in pulmonary TB. Weighted gene co-expression network analysis (WGCNA) (41) was used 225 
to explore relationships between clusters of highly correlated proteins (colour modules) and specific 226 
sample traits. Technical and biological variables of batch, smoking history and ethnicity were 227 
evaluated as possible confounders in the data using hierarchical clustering. The resulting dendrogram 228 
demonstrated that disease status was the primary determinant of sample clustering (Supplementary 229 
figure 5A). In order to select highly interconnected proteins exhibiting the strongest correlation with 230 
the disease status, detection of modules was performed (Supplementary figure 5B). The dendrogram 231 
of the topological overlap matrix (TOM) representing clusters of highly interconnected proteins with 232 
assigned colour modules and association to particular traits, demonstrated that the protein module 233 
turquoise was strongly associated to disease status (Figure 3B, Z score = -0.87; p-value = 2x10-07). 234 
One hundred and eighty nine proteins were contained in the turquoise module (Supplementary table 235 
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4) of which 129 (65.8%) were common to the differentially expressed proteins defined with LIMMA 236 
(7 protein unique to LIMMA and 60 unique to WGCNA). Gene ontology enrichment was performed 237 
using the package clusterProfiler (42) on the turquoise module and demonstrated that proteins profiled 238 
were mainly associated to a variety of intracellular and secretory vesicles, extracellular matrix, blood 239 
microparticles and lipoprotein particles (Figure 3C). Analysis revealed four main hubs for the top 20 240 
biological processes: inflammatory/acute-phase response, exocytosis/vesicle-mediated transport, lipid 241 
transport and proteolysis (Figure 4).  242 
 243 
To generate the most robust list of candidates for validation, we identified proteins in common 244 
between the module turquoise derived from WGCNA and significant by empirical Bayes moderated t-245 
statistics in LIMMA, thereby combining co-expression analytical approaches and t-statistics. 246 
Combining the approaches, we identified 26 common proteins with increased and 20 proteins with 247 
reduced abundance, with a high predicted significance (full list, Supplementary table 5; log2 Fold 248 
change ≥|0.5|; WGCNA: Z score ≥ |0.65| and p-value ≤0.05; LIMMA: q-value ≤0.05). This highly 249 
stringent approach is likely to omit numerous other differentially regulated proteins, but maximises 250 
the chance of subsequent validation for diagnostic use. Proteins in this list are associated to a wide 251 
range of biological processes, including acute inflammatory response, defence response to bacterium, 252 
lipid localisation, cell adhesion and regulation of peptidase activity (Figure 5). 253 
 254 
Host plasma proteins exhibit increased abundance in TB and other respiratory diseases 255 
Circulating levels of five proteins amongst the top 15 proteins with increased expression levels (Table 256 
1) were subjected to independent verification with ELISA or luminex array. C-reactive protein (CRP) 257 
and serum amyloid A1 (SAA1) were included in the verification panel as these are considered 258 
established major acute-phase effectors and are expected to increase in individuals with pulmonary 259 
TB. Lipopolysaccharide binding protein (LBP) and leucine rich alpha-2-glycoprotein 1 (LRG1) have 260 
been described in other proteomic TB profiles (11, 43, 44); therefore, the expression of these proteins 261 
on specific cohorts may add valuable information for the design of a multi-marker panel. Newly 262 
identified proteins from our analysis such as complement factor H related 5 (CFHR5) were 263 
additionally selected for verification. Proteins closely biologically associated to the selected proteins 264 
were excluded for further verification such as serum amyloid A2 (SAA2), since independency is 265 
recognised to benefit performance of multi-marker panels. In addition to these selected candidates, the 266 
seven most consistently divergently regulated proteins, analysed by fold change,  derived from the 267 
profile of HP-SEC segments 1 to 3 were included, RPGRIP1L, FGL1, COMP, KCNN2, TNFSF11, 268 
LTN and ILF2, to compare verification efficiency between the smaller and larger discovery groups.  269 
First, we studied a UK-recruited independent cohort of mixed ethnicity from the Multifunctional 270 
Integrated Microsystem for rapid point-of-care TB IdentifiCation (MIMIC) study, for verification of 271 
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selected candidates. CFHR5, LRG1, LBP, SAA1 and CRP showed significantly increased levels of 272 
expression in active TB patients when compared to healthy controls or latently infected individuals 273 
(Figure 6A-E). Evaluation of the markers selected from the initial discovery experiment on seven 274 
samples showed that RPGRIP1L, FGL1, COMP, KCNN2 and TNFSF11 failed verification 275 
(Supplementary figure 6). LTN (Supplementary figure 7, p-value = 0.04) abundance was significantly 276 
higher in TB patients. Additionally, ILF2, identified from segment 3 analysis, showed elevated 277 
abundance in latent TB and active TB patients compared to healthy donors (Figure 6F, p-value = 278 
0.0005).  Consequently, two out of seven proteins successfully verified from the smaller discovery 279 
group, whereas all were verified from the larger discovery group.   In addition to being elevated in 280 
TB, patients with other respiratory diseases (ORD) also exhibited elevated abundance in all verified 281 
markers (Figure 6A-F).  282 
Diagnostic performance of individual and combined verified markers was evaluated using Receiver 283 
Operator Characteristic (ROC) curves. ROC curves were generated based on two different 284 
comparisons; circulating level of markers in active TB patients vs. healthy controls (Figure 7A) and 285 
active TB patients vs. ORD patients (Figure 7B). In both cases, the best performance was achieved by 286 
combining the 5 markers (CFHR5, LRG1, LBP, SAA1 and CRP). The area under the curve (AUC) 287 
was 0.93 (95% confidence interval: 0.89-1.00, p-value ≤ 0.001) for TB vs. healthy controls and 0.81 288 
(95% confidence interval: 0.68-0.94, p-value = 0.001) for TB vs. ORD, thus demonstrating that only 289 
the combination of markers allowed the discrimination of active TB from healthy controls and ORD. 290 
Although ILF2 abundance was significantly upregulated in the active TB and ORD patients from this 291 
cohort (Figure 6F), it did not contribute towards a better diagnostic performance of the panel. 292 
We then further verified the biomarkers in a South African cohort, which included HIV-uninfected 293 
and HIV-infected active TB and ORD patients. Again, the novel diagnostic marker CFHR5 exhibited 294 
significant increased abundance in HIV-uninfected patients.  In HIV co-infected patients, CFHR5 was 295 
elevated compared to healthy controls, but not significantly different to healthy HIV-infected 296 
individuals, although this group had limited numbers (Figure 8A).  CFHR5 showed no significantly 297 
increased abundance in ORD, irrespective of HIV status. Again, interpretation may be due to limited 298 
sample numbers reducing statistical power. LBP and SAA1 both showed increased abundance in the 299 
active TB group regardless of HIV status. This trend was observed relative to the ORD group HIV un- 300 
and co-infected (Figure 8B-C). CRP showed increased abundance in TB compared to healthy controls 301 
and ORD groups, irrespective of HIV status (cohort data previously published (7)). In this cohort, 302 
ILF2 and LRG1 could not be measured due to sample exhaustion and were thus excluded from the 303 
panel. A summary of the analytes tested in each cohort and verification results is presented as 304 
Supplementary table 6.  305 
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ROC curves generated by comparing circulating levels of CFHR5, LBP, SAA1 and CRP in TB 306 
patients vs. ORD in the HIV uninfected group showed that the best performance was achieved by 307 
combining markers (Figure 9A, AUC 0.89 [95% confidence interval: 0.80-0.98, p-value ≤ 0.001]). 308 
Similarly, in the context of HIV-associated TB, the combination panel performed best, and provided a 309 
surprisingly high discrimination between active TB and ORD (Figure 9B, AUC 0.98 [95% confidence 310 
interval: 0.94-1.00, p-value ≤ 0.001]). By contrast, the combination of markers did not improve the 311 
diagnostic performance when the active TB group was analysed against the healthy controls relative 312 
to analysis of CRP alone (Supplementary figure 8). Finally, we evaluated whether our 4-protein panel 313 
correlated to sputum mycobacterial load in the South African cohort. Mean Z-scores were calculated 314 
from CFHR5, LBP, SAA1 and CRP levels in TB patients (HIV negative) and compared to the 315 
bacterial burden in sputum. A significant positive correlation was observed (Spearman coefficient r = 316 
0.37, p-value = 0.03).  317 
  318 
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Discussion 319 
We applied a unique non-depletion based quantitative proteomics method (q3D LC-MS) to generate 320 
the most comprehensive TB plasma proteome to date.  Statistical power was increased by studying 321 
one HP-SEC segment in additional patients and combined WGCNA and LIMMA analysis 322 
approaches, identified numerous novel host biomarkers with high confidence.  We verified a subset of 323 
biomarkers in two separate cohorts, with high success rate.  Diagnostic accuracy for TB was 324 
maximised by use of a multi-marker panel.  These markers are frequently also increased in other 325 
respiratory conditions and therefore host biomarkers are likely to be of greatest use in a rule-out panel.   326 
Translation of novel biomarkers for clinical utility is challenging, involving a stepwise process where 327 
most candidates fail to reach the bedside. Verification of new candidates typically relies on antibody-328 
based assays, requiring change of platform from mass spectrometry to immunoassays prior to field-329 
testing, and this is frequently a point of failure. We completed this transition for three new analytes, 330 
thereby supporting the robustness of the approach.  Validation will require quantification of the 331 
additional 15 entirely new biomarkers in the top candidates (Figure 5, Supplementary table 5) 332 
identified by the combined WCGNA and LIMMA approaches, and inter-laboratory collaboration 333 
across large cohorts from multi-centre biobanks, including analysis of how biomarkers relate to 334 
disease severity and change over time. 335 
Plasma is a complex matrix to analyse, and high-abundant protein depletion is the most common 336 
strategy to address this complexity (5, 27-29, 45, 46).  However, depletion may inadvertently co-337 
remove important analytes non-covalently bound to high abundance proteins (26). In this study, 338 
sample preparation was principally based on the use of orthogonal chromatographic hyper-339 
fractionation instead of depletion. Such a strategy entailed the dissolution of 120μL neat plasma with 340 
7M guanidine/10% methanol that stabilised the protein content and was subjected to HP-SEC 341 
separation as part of the hyper-fractionation pipeline. The use of multi-dimensional liquid 342 
chromatographic approaches as part of the isobaric quantitative proteomics pipeline has gained 343 
increasing prominence in translational research studies (47). Such approaches compensate for the 344 
complexity of biological specimens in capturing and analysing very low abundant proteins of clinical 345 
significance. Furthermore, they are amenable to laboratory automation and scale-up, thus improving 346 
analysis throughput, accuracy and precision (47, 48). In line with this, the collective attributes of the 347 
present study method facilitated the analysis of proteins encompassed in blood microparticles, such as 348 
exosomes and other lipid vesicles (27, 28), along with protease derived cleavage proteins and soluble 349 
proteins. The efficacy of our approach was demonstrated by the profiling of over 5,000 proteins from 350 
only 120μL plasma per patient, compared to the identification of a maximum of 800 proteins in 351 
similar TB discovery studies from larger volumes of plasma (16, 20, 49).  Most importantly, however, 352 
the deep proteome coverage achieved also encoded for a wide spectrum of biological and disease 353 
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specific pathways and networks of physiological relevance to TB. Encompassed in these pathways 354 
and networks were many novel proteins of potential clinical significance. 355 
Analysis of the entire proteome from HP-SEC segments 1 to 4 using seven samples was 356 
underpowered for biomarker discovery, with only two out of seven candidates subsequently validating 357 
on a larger cohort. Therefore, detailed profiling was focused on the sub-proteome segment 4, which is 358 
primarily enriched for low-molecular weight proteins and protein degradation products, recapitulating 359 
multiple biological processes (28, 29, 50-52). In-depth profiling of this segment from 10 healthy 360 
controls and 11 pulmonary TB patients provided much greater statistical power, consistent with 361 
mathematical estimations (38). The high-dimensional data produced from isobaric labelling-based 362 
relative quantification (iTRAQ or TMT) poses bioinformatic processing challenges (34). Small 363 
sample sizes, incomplete datasets and batch effects across experiments create difficulties in the 364 
effective detection of protein abundance changes (35).  Batch effects are particularly relevant to 365 
multiplexing of iTRAQ experiments.  In our study, Combat correction performed better than the most 366 
common strategy of normalizing to a common reference sample (Supplementary figure 4). 367 
Complementary analysis using LIMMA and WGCNA on the adjusted data resulted in a powerful 368 
approach producing a set of robust markers for verification (Supplementary table 5), with three out of 369 
three tested proteins successfully converting to an immunoassay platform, compared to two out of 370 
seven from the smaller sample set (Set A profile).  Thus, this methodology led to the identification 371 
and independent verification of known and novel candidate biomarkers of TB infection.  372 
WGCNA identified one co-expression module as strongly associated to the group TB (turquoise 373 
module, p-value = 2x10-07) containing 189 proteins. Ninety-five percent of the differentially expressed 374 
proteins identified with LIMMA were common to this module, showing excellent concordance 375 
between analytical strategies. Notably, over 60% of the co-expressed proteins showed decreased 376 
abundance in the active TB group, suggesting that studying these proteins may provide additional 377 
insight into disease process in TB, and analysis should not purely focus on proteins of increased 378 
abundance. Gene ontology enrichment of module turquoise revealed regulation of biological 379 
processes associated to responses to external stimulus (q value = 2x10-03) encompassing acute-380 
phase/inflammation (q value = 5.2x10-06) and humoral responses (q value = 9.2x10-05).  Within this 381 
module, CRP, LBP, SAA1, SAA2, S100A8, S100A9, SERPINA3 and HP are involved in the 382 
activation of the acute-phase and inflammatory response, which are well described in TB (20, 53, 54).  383 
This concordance supports the overall validity of our methodology. 384 
Connected to the acute-phase hubs, proteolysis (q value = 1.1x10-06) and lipid transport and localisation 385 
(q value = 1.4x10-05) were significantly enriched.  Proteolysis is consistent with the extensive pulmonary 386 
destruction that occurs in human TB (55). Among the proteins with increased abundance in this hub, 387 
ECM1 was previously reported elevated in saliva of TB patients (56), MMP-14 is expressed in TB 388 
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granulomas (57) and PSMB8 may be part of the regulatory cascade of the blood transcriptome of TB 389 
patients (58). Among the proteins found with decreased abundance, TIMP2 is an inhibitor of matrix 390 
metalloproteinases, and so reduced levels may increase matrix degradation (55). Lipid metabolism was 391 
another major signal expressed, and the role of lipids and cholesterol in TB immunopathology remains 392 
poorly characterised. Cholesterol uptake and catabolism are central for maintenance of the pathogen in 393 
the host and contribute to pathogenesis and virulence (59). However, the low circulating lipid profiles 394 
in pulmonary TB patients may be a consequence of the disease or may have wider biological 395 
implications. Apolipoproteins are associated to lipid transport and form lipoprotein particles such as 396 
HDL, LDL and VLDL. Serum HDL-C concentrations negatively correlate with the radiological extent 397 
of disease and smear positivity in pulmonary TB (60). Decreased circulating concentrations of 398 
apopoliproteins are consistently reported in different serum/plasma proteomic profiles for pulmonary 399 
TB (11-13), in agreement with our findings. Further data mining of these biological processes may 400 
identify host-directed therapy targets. 401 
To verify newly-identified biomarkers, well-characterised TB cohorts with complementary profiles and 402 
from geographically diverse populations are required (4). We studied two different cohorts for 403 
verification, one recruited in the UK and one in South Africa. From the subset of proteins analysed by 404 
ELISA or luminex, seven proteins were successfully validated. LBP, CFHR5, CRP and SAA were 405 
consistently increased in TB cases in both cohorts. Statistically significant differences were observed 406 
despite the wide inter-individual variation in biomarker concentrations, which is expected from clinical 407 
TB which has a wide spectrum of disease severity.  ILF2 was only verified in the MIMIC cohort due to 408 
sample exhaustion, while LTN and LRG were only evaluated in the South African cohort. CFHR5 409 
(complement factor H-related protein 5), ILF2 (Interleukin Enhancer Binding Factor 2) and LTN (E3 410 
ubiquitin-protein ligase listerin) are novel protein candidate biomarkers for TB identified by the 411 
discovery phase and all were successfully verified. Consistent with our findings, a recent report 412 
identified ILF2 as a potential biomarker in paediatric TB by bioinformatic mining of gene expression 413 
datasets (61).  414 
Evaluation of the performance of a subset of markers indicated than combination rather than 415 
individual markers provided a better diagnostic ability. In the UK-based cohort, ROC analysis 416 
demonstrated that the multi-marker panel comprising CFHR5, LRG1, CRP, LBP and SAA1 417 
performed well in receiver operator curve analysis against healthy controls (AUC = 0.93). However, 418 
the discriminatory power was reduced but still significant when compared against other respiratory 419 
diseases (AUC = 0.81). Clinically, differentiation against other respiratory conditions is the key 420 
comparator for TB diagnosis. Host biomarkers are often limited by lack of specificity and our findings 421 
reinforce the importance of choosing correct control groups for verification analysis (18). In the South 422 
African cohort including patients with and without HIV infection, the multi-marker panel comprising 423 
LBP, CFHR5, CRP and SAA yielded its best performance when TB patients where compared to other 424 
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respiratory diseases (AUC=0.98).  This is an important finding from a clinical perspective, as 425 
diagnosing TB in HIV-infected patients is generally more challenging than in non-426 
immunocompromised individuals (2). Furthermore, performance of our panel in both cohorts (UK and 427 
South Africa) comparing ATBI to ORD groups was similar to a different recently validated host 428 
response signature (IL6, IL8, IL18 and VEGF, AUC=0.80) (62).  This suggests our preliminary 429 
signature can be further refined by testing of remaining highly significant candidates that have not yet 430 
been studied. The primary difference between the groups is that the UK cohort were hospitalised 431 
patients, whereas the South African cohort were outpatients, and therefore the better performance in 432 
South Africa may reflect the fact the patients were less unwell.  For utility of a point-of-care test, 433 
outpatients with respiratory symptoms will be the primary target group.   434 
Significant efforts have been directed to define an optimal plasma protein biosignature for active TB 435 
and recently, extensive testing of candidate proteins identified by predefined discovery panels, such 436 
those measured with luminex, have shown that multi-component or multi-factorial signatures could 437 
give a greater performance than immunological markers despite the heterogeneity of clinical 438 
presentation (62, 63). Inclusion of novel markers that represent the biological diversity of the host 439 
response to the Mtb infection in diagnostic panels may be crucial to achieve the analytical 440 
performance required to translate to effective point-of-care devices. From our top list of 46 proteins 441 
identified by both LIMMA and WGCNA from the discovery phase (Supplementary table 5), 21 442 
proteins are entirely novel candidates and involved in a wide range of biological processes.  443 
Consequently, verification and integration with known markers may improve the performance of the 444 
existing signatures. This list recapitulated several potential diagnostic biomarkers identified in a range 445 
of reported plasma proteomic TB signatures (11, 13, 14, 20, 44, 64), including one signature for TB 446 
progression (17), one for cured pulmonary tuberculosis (21) and one for multidrug-resistant TB (65), 447 
demonstrating the ability of our proteomic and bioinformatic approach to detect proteins associated to 448 
the disease status, independent  of differences in discovery platforms or patient cohorts. However, 449 
further verification of all the newly reported candidates that we identify is required to refine the 450 
current panel.  451 
Translation of such markers to point-of-care tests with adequate performance will require the 452 
development of multiplex lateral flow assays, and such platforms are currently emerging (66, 67), 453 
though will require careful development. Any assay used as a rule-out test would need population-454 
based studies to confirm the specificity against standard current clinical practice and emerging blood 455 
protein-based signatures. Due to the overlap between TB and other respiratory conditions, the host 456 
biomarkers identified are potentially best utilised as a rule-out triage test prior to performing more 457 
specific and expensive rule-in tests (68). In the future, analysis of other proteins that are differentially 458 
abundant will become increasingly achievable, given the continuous advancements of LC-MS 459 
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methods in terms of throughput and analytical confidence. When combined with machine learning 460 
approaches, LC-MS based assays may transform specificity and sensitivity in the diagnosis of TB.  461 
In summary, we developed a non-depletion based proteomic methodology to deeply profile plasma 462 
and identify novel biomarkers. We present a unique statistical and bioinformatic pipeline for 463 
discovery and selection of candidates for verification that utilises both statistical significance and also 464 
correlation of expression patterns to clinical traits.  We report numerous novel analytes, with potential 465 
to be translated for clinical utility. We have verified a subset of biomarkers from segment 4 by 466 
independent antibody-based assays to generate a preliminary diagnostic panel, and similar 467 
interrogation of segments 1 to 3 is likely to generate further novel biomarkers.  Taken together, 468 
developing these host biomarkers into a multiplex lateral flow assay has potential for a near-patient 469 
TB rule-out test that fulfils the WHO product characteristics. Such an assay could be a powerful tool 470 
to address the global TB pandemic. 471 
  472 
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Methods 473 
Study Participants 474 
This study included participants from three different cohorts. The participants from the South African 475 
cohort were recruited at Ubuntu HIV/TB clinic in Cape Town and were black-African ethnicity from 476 
June 2012 to February 2014. Written informed consent was obtained, HIV testing was offered, and 477 
chest radiographs were performed as per routine practice. The diagnosis of active TB was based on 478 
sputum smear or culture positivity, Gene Xpert results (where available) and chest X-ray examination. 479 
For the control group, all sputum samples were smear and culture negative for acid-fast bacilli (AFB). 480 
Plasma samples from this cohort were retrospectively selected from a cohort collected and previously 481 
described (7). Participants from this cross-sectional study were categorised into six groups: i) HIV-482 
uninfected patients without active TB infection (HIV- ATBI -); ii) HIV-uninfected patients with 483 
active TB infection (HIV- ATBI +); iii) HIV-uninfected patients without active TB but with 484 
symptoms attributable to other respiratory infectious disease (HIV- ORD); iv) HIV-infected without 485 
active TB infection (HIV+ ATBI-); v) HIV-infected with active TB infection (HIV+ ATBI+) and vi) 486 
HIV-uninfected patients without active TB but with symptoms attributable to other respiratory disease 487 
(HIV+ ORD). Microbiological confirmation of the infectious agent was not available for the HIV-488 
/HIV+ ORD groups due to limitations in local diagnostic capability.  A randomly selected subset of 489 
11 plasma samples from male participants belonging to the groups HIV- ATBI - and HIV- ATBI + 490 
was used for discovery (Supplementary table 1). A larger set of 203 samples from all six groups and 491 
including those used for discovery constituted the South African verification cohort and demographic 492 
description of this group has been previously reported with CONSORT diagram (7).   493 
Participants from the Peruvian discovery cohort were prospectively recruited at clinics in Lima, Peru 494 
to match demographic features such as gender, age and BMI of participants from the South Africa 495 
cohort. Recruitment was conducted during 2015. The diagnosis of active TB was based on a TB 496 
symptom questionnaire, sputum smear positivity, culture positivity using microscopic-observation 497 
drug-susceptibility (MODS) culture and chest X-ray. Healthy control individuals were Quantiferon 498 
negative. In total, 10 samples from this cohort were selected for the discovery stage of this study 499 
(Supplementary table 1). 500 
A second independent cohort was included for verification of proteomic candidates comprising a 501 
subset of 118 participants from the Multifunctional Integrated Microsystem for rapid point-of-care TB 502 
Identification (MIMIC) cross-sectional study conducted in the United Kingdom. Recruitment was 503 
performed from June 2014 to February 2017. All the participants were HIV uninfected and four 504 
categories were defined for this cohort: i) Healthy controls (HC), ii) Latent TB infection (LTBI); iii) 505 
Active TB infection (ATBI) and iv) Other respiratory diseases (ORD).  Healthy controls were 506 
asymptomatic individuals without a history of previous active TB or TB contact and no evidence of 507 
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TB infection on routine screening tests (negative interferon-gamma release assay and/or tuberculin 508 
skin test result). Participants with latent TB infection were defined based on a positive interferon-509 
gamma release assay and/or tuberculin skin test result, without evidence of active disease after clinical 510 
evaluation. All active pulmonary TB cases were individuals with symptomatic respiratory infection 511 
that were microbiologically-confirmed to have TB based on any of the following criteria: sputum 512 
smear positive, sputum culture positive for Mtb, or PCR test positive for Mtb. The control group other 513 
respiratory diseases (ORD) were symptomatic individuals with microbiologically-confirmed 514 
respiratory tract infection caused by a pathogen (viral or bacterial) other than Mtb, without a history of 515 
previous active TB (Supplementary table 7). The microbiological composition of this group was 31% 516 
influenza A/B, 15% Streptococcus pneumonia, 8% respiratory syncytial virus, 8% Staphylococcus 517 
aureus, 4% Mycoplasma pneumonia, 4% Human Metapneumovirus, 4%  H1N1 Influenza A, 4%  518 
Methicillin-resistant Staphylococcus aureus and 22% unidentified organism.  519 
Plasma processing 520 
Venous blood was collected in sodium citrate vacutainer tubes and plasma prepared according to 521 
standard operating procedures at the site of recruitment and stored at -80°C.  Aliquots of 120µl of 522 
plasma were liquid–fixed with 380µl of 7M guanidine hydrochloride and 10% methanol and stored at 523 
-20°C until size exclusion chromatography fractionation was performed for the discovery stage. 524 
Aliquots of 20µl of the individual samples available for discovery including control and active TB 525 
groups was combined to generate a master pool aimed to control batch effects across different MS 526 
experiments. All the plasma samples included in the verification stage were divided into 100µl 527 
aliquots to reduce freeze-thaw cycles when received and stored at -80°C until analysis. 528 
Multidimensional plasma proteomic analysis 529 
High-performance size exclusion chromatography (HP-SEC) 530 
A general overview of the plasma proteomic method is presented in Supplementary figure 1A. Plasma 531 
samples used for discovery, including four aliquots of the master pool, were individually subjected to 532 
HP-SEC pre-fractionation under optimised conditions of the method reported previously (28). Five 533 
columns were serially connected: 2 Shodex KW-804 columns, 8.0mm I.D. x 300mm; one Shodex 534 
KW-802.5 column, 8.mm I.D. x 300mm; and 2 Shodex KW-804 columns, operated at 45°C and 535 
1.5mL/min under isocratic elution with 6M guanidine hydrochloride and 10% methanol. Four protein 536 
HP-SEC segments were collected in a peak-dependent fashion detected at 280nm and then stored at    537 
-20°C until further analysis. HP-SEC separations are presented in Supplementary figure 2A-E. The 538 
BEH450 SEC protein standard Mix (Waters, UK) and an aliquot of one control plasma sample were 539 
run for day-to-day quality control of the separation variation (Supplementary figure 2F).  Variation of 540 
retention times was within 2SD for all samples excepting one (Supplementary figure 2G). Protein 541 
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segments were dialysis-purified using 3KDa MWCO Slide-A-Lyzer cassettes according to 542 
manufacturer’s specifications (Thermo Fisher, Hemel Hempstead, UK) with exchanges of four 543 
volumes of 4L of ultrapure water every 12h intervals in a cold room environment (4°C). The resulting 544 
dialysates were completely lyophilised using the Edwards Modulyo EF4-174 freeze dryer and Thermo 545 
Savant Micro Modulyo-115 benchtop freeze dryer. Protein extracts were stored at -80°C under argon 546 
atmosphere. 547 
Trypsin digestion 548 
Total protein lyophilised extracts obtained from each HP-SEC segment were reconstituted with 0.5M 549 
TEAB (triethylamonium bicarbonate) and 0.05% SDS (sodium dodecyl sulfate) and sonicated on ice. 550 
Protein extracts were then centrifuged for 10 minutes at 16000xg and 4°C and protein content in the 551 
supernatants was estimated using the Nanodrop ND-1000 spectrophotometer (Thermo Fisher 552 
Scientific, Wilmington, USA) using the A280 program. 120µg of protein volume-adjusted were 553 
reduced with 2µL of TCEP (50mM tris-2-carboxymethyl phosphine) and incubated for 1h at 60°C. 554 
Reduced samples were then alkylated using 1µL of MMTS (200mM methylmethane thiosulphonate) 555 
and incubated 10 minutes at room temperature. Digestion was conducted to a ratio of 1:40 556 
enzyme/substrate with trypsin MS grade (Pierce, Thermo Fisher Scientific, UK) overnight for 16h at 557 
37°C in dark. 558 
Stable isotope labelling  559 
iTRAQ 8-plex tags were equilibrated at room temperature and isopropanol was added accordingly to 560 
ensure >60% organic phase during labelling. Each tag was added to the appropriate trypsinised 561 
sample, then the labelling reaction was conducted for 2h at room temperature. The reaction was 562 
stopped with 8µL of 5% ammonium hydroxylamine. Samples were dried and stored at -20°C until 563 
chromatographic separation.  The master pool was labelled using the tag 113 and the samples were 564 
allocated randomly to the remaining tags as presented in the Supplementary figure 2A.  565 
Offline alkaline RP-HPLC peptide fractionation  566 
Offline peptide fractionation was based on high pH (0.08% v/v NH4OH) reverse phase (RP) 567 
chromatography using the Kromasil C4 column (3.5μm, 2.1mm x 150mm) and on the Shimadzu 568 
HPLC system previously described in the HP-SEC section. iTRAQ labelled tryptic peptides were 569 
analytically reconstituted and pooled together with 100µL of mobile phase, centrifuged at 16000xg at 570 
room temperature for 10 minutes. Supernatant was injected and separated at a flow rate 0.30mL/min 571 
and 30°C. The fractions were collected in a peak-dependent fashion detected at 215nm. Peptide 572 
fractions were dried at room temperature with a speedvac concentrator for 4−5h and stored at −20°C 573 
until LC−MS analysis. Highly hydrophilic and hydrophobic fractions from the extreme regions of the 574 
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chromatographic traces were pooled and further cleaned using Gracepure SPE C18-AQ 100mg/1mL 575 
cartridges (Grace, Columbia, USA).  576 
LC-MS analysis 577 
The LC−MS experiments were performed on the Dionex Ultimate 3000 UHPLC system coupled to 578 
the high resolution nano-ESI-LTQ-Velos Pro Orbitrap-Elite mass spectrometer (Thermo Fisher 579 
Scientific). HCD and CID fragmentation for each of the collected fractions was performed. For the 580 
analytical separation the AcclaimPepMap RSLC, 75μm × 25 cm, nanoViper, C18, 2μm particle 581 
column (Thermo Fisher Scientific) with trap cartridge retrofitted to a PicoTip emitter (FS360-20-10-582 
D-20-C7) was used for multistep gradient elution. MS characterization of eluting peptides was 583 
conducted between 380 and 1500 m/z. The top ten +2 and +3 precursor ions were further 584 
characterised by tandem MS. Full MS scans and MS/MS scans were acquired at a resolution of 585 
30000FWMH (complete plasma proteome) or 60000FWMH (detailed analysis segment 4) for profile-586 
mode and 15000FWMH for centroid-mode, respectively, with the lock mass option enabled for the 587 
445.120025m/z ion (DMSO). Data were acquired using Xcalibur software (Thermo Fisher Scientific). 588 
Conditions for ionisation, CID and HCD fragmentation and ion detection were reported in a previous 589 
work (28).  590 
MS data processing 591 
Target-decoy searching of raw mass spectra data was conducted with the Proteome Discoverer 1.4 592 
software (Thermo Fisher Scientific). SequestHT was used for the target decoy search for tryptic 593 
peptides, allowing two missed cleavages, 10ppm mass tolerance, and minimum peptide length of 6 594 
amino acids. A maximum of 2 variable (3 equal) modifications; oxidation (M), deamidation (N, Q) 595 
and phosphorylation (S, T, Y) were set as dynamic modifications. As static modifications were set: 596 
iTRAQ8plex (Any N-terminal), Methylthio (C) and iTRAQ8plex (K). Fragment ion mass tolerance 597 
was set to 0.02Da for the FT-acquired HCD spectra and 0.5Da for the IT-acquired CID spectra. FDR 598 
was estimated with the Percolator (6.4Bit) and validation was based on q-value <0.01 for high 599 
confidence or <0.05 for moderate confidence. All spectra were searched against a concatenated 600 
FASTA file including the reviewed UniProtKB SwissProt human proteome and the reference 601 
proteome (SwissProt and TrEMBL) for Mtb (strain ATCC 25618 / H37Rv), both retrieved on 04 602 
August 2017. All peptide spectrum matches (PSM) of reporter ions and iTRAQ ratios were exported 603 
to .txt at 1% FDR or 5% FDR peptide confidence and 50% co-isolation exclusion threshold. Protein 604 
grouping was allowed and maximum parsimony principle was applied. Only unique peptides were 605 
considered for quantification downstream analysis. Raw precursor ion intensities from unique 606 
peptides were imported to R (version 3.3.1) and median-adjusted. Median-normalised peptide 607 
intensities were log2-transformed and values were averaged to obtain the mean relative expression for 608 
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each protein. Only proteins with relative quantification reported in all the samples was included for 609 
statistical analysis. 610 
ELISA and luminex assays 611 
Proteins selected for verification from the proteomic discovery experiments were measured in two 612 
different cohorts using ELISA or luminex assays. ELISA measurements comprised candidates for 613 
which there are commercially available kits, such as: RPGRIP1L, FGL1, COMP, ILF2, KCNN2, 614 
LTN1, LRG1 and SFTPB (2B Scientific Ltd, Upper Heyford, UK and Caltag Medsystems Ltd, 615 
Buckingham, UK). One luminex multiplex assay was custom-made for analysis of LBP, COMP, 616 
TNFSF11 and CFHR5 and two single-plexes for SAA1 and CRP (Protavio Ltd, Cambridge, UK). CV 617 
for the ELISA assays was ≤12% and for the luminex assays was ≤15%. Assays were performed 618 
according to manufacturer’s directions.  619 
ROC curves and AUC analysis 620 
Performance of the validated candidates was in first instance assessed by calculating receiver 621 
operating curves (ROC) for individual proteins and combined proteins in each verification cohort. The 622 
statistical package SPSS Statistics 25 (IBM, Armonk, US) was used for this purpose. ROC analysis 623 
was conducted by setting pulmonary TB as a positive test and binary logistic regression probabilities 624 
were calculated when analysis of combined markers was performed. Coordinates of the curves was 625 
exported to estimate potential cut-off values.  626 
Statistics 627 
Differentially expressed proteins (DEPs) were determined using linear modelling LIMMA (69) 628 
followed by FDR correction for multiple correction testing. WGCNA-based analysis was applied to 629 
the datasets resulting from the detailed profile of segment 4 to interpret biologically relevant patterns 630 
of protein expression in plasma of patients with pulmonary TB. The WGCNA R package was used to 631 
explore the correlation relationships between clusters of highly correlated proteins (colour modules) 632 
and specific sample traits. The batch effect was corrected in order to increase the analysis power with 633 
ComBat (40). Networks of highly interconnected proteins were constructed using a soft-thresholding 634 
power = 0.9 and modules were identified using a minimum module size of 15. Module significance 635 
was calculated as a measurement of the correlation between biological traits, such as disease or group, 636 
ethnicity and smoking status and the protein expression profiles. Visualisation tools available from 637 
this package were used to identify modules strongly correlated to biologically relevant covariates. 638 
Functional enrichment analysis was conducted using the option g:GOSt available in the tool g:Profiler 639 
(70). Only GO terms with an FDR adjusted p-value (cut-off 0.05) were considered. Significant GO 640 
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terms were summarised by removing redundant terms using the tool REVIGO (71). C-Net plots were 641 
generated using the R package cluster profiler (72). 642 
For ELISA and luminex measurements, differences between groups were analysed by Kruskal-Wallis 643 
tests and using Dunn’s multiple comparison correction. Data was analysed on Prism 8 (GraphPad, San 644 
Diego, US). A p-value ≤0.05 was considered statistically significant. For the ROC analyses, the 645 
nonparametric method was used to estimate the standard error of the area under the curve and the 646 
confidence interval was set at 95%.  647 
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Fig. 1. Overview of the plasma proteomic discovery and validation strategy of potential TB 925 
biomarkers. 926 
(A) Identification and quantification of plasma proteins was performed using a quantitative 927 
multidimensional protein identification approach which comprises a series of fractionation steps at 928 
both protein (denaturing HP-SEC) and peptide level (offline high pH C4 HPLC followed by online 929 
low pH C18 UPLC). Initial plasma prefractionation using HP-SEC produces 5 segments depending on 930 
the molecular size. Only segments 1 to 4 were included in this study since these include most of the 931 
protein contents. (B) Bioinformatic processing prioritised markers, which were then measured by 932 
ELISA or luminex in plasma or serum samples from two cohorts. Discovery and validation stages 933 
involved multiple ethnicities. 934 
 935 
Fig. 2. In-depth quantitative plasma proteome profiling in TB. 936 
(A) Violin plots with median and interquartile range show molecular weight frequency distributions 937 
of proteins quantified (peptide confidence ≤1%FDR) in each independent HP-SEC segment. The 938 
number of proteins with relative quantitative data in all profiled samples is indicated. Four plasma 939 
samples from TB patients, three healthy controls and one master pool were analysed. (B) Abundance 940 
of quantified proteins from all HP-SEC segments. Only proteins with circulating levels reported in the 941 
reference PaxDb1.4 protein abundance database or in the literature were annotated. Proteins 942 
considered as classical plasma proteins are indicated in red, tissue leakage proteins in green, proteins 943 
with signalling functions in purple and proteins associated to extracellular vesicles in yellow. 944 
Concentrations of detected proteins span 11 orders of magnitude. (C) Principal component analysis 945 
based on quantified proteins from all HP-SEC segments of eight profiled samples. iTRAQ tags and 946 
groups are indicated. Overall, TB patients were separated from healthy controls by the principal 947 
component PC1 and PC2, collectively explaining the 62% of total variance. The TB sample labelled 948 
with tag 121 clustered with the healthy control samples. The master pool, a combination of all 949 
samples, was located in the centre of the samples. (D) Log2 transformed relative protein expression 950 
heatmap of all proteins profiled in the four HP-SEC segments. Purple indicates TB patients and green 951 
healthy controls. Pearson correlation was used for clustering of proteins and Spearman for samples. 952 
Two clusters were defined based on the relative protein expression and GO analysis of these was 953 
performed using g:Profiler. Cyan: downregulated proteins; Magenta: upregulated proteins. 954 
 955 
Fig. 3. Detailed profiling of segment 4 identifies a differential plasma proteome in TB infection. 956 
Analyses of common quantified proteins (peptide confidence FDR ≤ 0.01) derived from HP-SEC 957 
segment 4 across three iTRAQ experiments studying 10 controls and 11 TB patients (n=426 proteins). 958 
(A) Volcano plot representation of plasma proteins differentially expressed in TB defined by LIMMA 959 
with FDR correction (q-value ≤0.05). Red indicates upregulated proteins and blue downregulated. 960 
Gene names of significantly regulated proteins with log2 fold change ≥|0.5| are shown. (B) WGCNA 961 
33 
 
cluster dendrogram of quantified proteins into distinctive modules defined by dendogram branch 962 
cutting. Colour modules indicate protein clusters of highly interconnected proteins associated to the 963 
disease status. Correlation score and significance demonstrates that module turquoise is strongly 964 
correlated to TB status. (C) Gene ontology enrichment of proteins included in the module turquoise 965 
(n=189). Dots represent the top 20 enriched cellular component organisation terms. Dot colour 966 
indicates significance (p-value Benjamini-Hochberg adjusted) and size represents the number of 967 
differential proteins in the significant gene list associated with the GO term.  968 
 969 
Fig. 4. Physiological changes in pulmonary TB are reflected in the plasma proteome. 970 
Functional enrichment analysis of the biological processes was performed on the one hundred and 971 
eighty nine proteins strongly associated to the TB status and identified by WGCNA. Gene-concept 972 
network (c-net plot) depicts the linkages of proteins and the top 20 biological process terms enriched 973 
in the turquoise module. Up-regulated and down-regulated proteins were included. Green-to-red 974 
coding next to the network indicates the log2FC. Proteins in bold were selected for validation. 975 
 976 
Fig. 5. Top candidate biomarkers for active TB link to multiple biological processes.  Chord plot 977 
for plasma proteins strongly correlated to active TB and identified by combining outputs from 978 
WGCNA and LIMMA. This plot links these proteins via ribbons to their associated biological 979 
processes. Blue-to-red coding next to the proteins indicates the log2FC. Gene ontology enrichment for 980 
biological process was performed in g:Profiler and only significant terms (FDR q-value ≤ 0.05) are 981 
shown. Plot generated with the R package GOplots. 982 
 983 
Fig. 6. Novel TB biomarkers validate in an independent UK cohort of mixed ethnicity. 984 
Two novel TB biomarkers were significantly upregulated in TB infection measured by luminex or 985 
ELISA in serum from an independent UK-based cohort. (A) CFHR5 (Complement factor H related  986 
protein 5) is increased in TB, and also significantly increased in other respiratory diseases (ORDs). 987 
Four known TB potential markers were measured and were significantly elevated in TB: (B) LRG1 988 
(Leucine-rich alpha-2-glycoprotein). (C) LBP (Lipopolysaccharide binding protein), (D) SAA1 989 
(Serum amyloid A1), (E) CRP (C-reactive protein). (F) ILF2 (interleukin enhancer binding factor 2), 990 
a novel analyte from segment 3, was elevated in TB and ORDs. Box displays 25% and 75% 991 
percentiles with line showing median, and whiskers displaying minimum to maximum values. 992 
Differences were considered significant when p-value <0.05 and calculated from Kruskal-Wallis test 993 
and Dunn’s multiple comparison test. HC: Healthy controls (n=30), LTBI: Latent TB infection 994 
(n=30), PTBI: Pulmonary TB infection (n=32) and OR: Other respiratory diseases (n=26).  995 
 996 
Fig. 7. Combination of five protein markers discriminates TB patients in a UK-based cohort 997 
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Receiver operator characteristic (ROC) curves were generated using SPSS v.25, for individual 998 
proteins (CFHR5, LBP, SAA, CRP and ILF2) and after binary logistic regression for combined 999 
analytes. AUC was estimated under nonparametric assumption. TB was set as the positive test 1000 
outcome and the test direction such that larger test result indicates a more positive test. ROC curve for 1001 
TB infection vs. healthy controls shows good discrimination, with the multiplex panel most 1002 
discriminatory (A), while the ROC curve for TB infection vs. ORD shows individual analytes are not 1003 
differentiating, but a combined multiplex generates an AUC of 0.813 (B). 1004 
 1005 
Fig. 8. CFHR5 validates as a new diagnostic marker of TB in HIV-coinfection, and multiplex 1006 
analysis performs well against other respiratory conditions. 1007 
(A) CFHR5 was significantly upregulated during active TB infection in a previously reported South 1008 
African cohort, in both HIV uninfected and HIV infected individuals. Three other potential TB 1009 
markers were also elevated: (B) LBP, (C) SAA1 and CRP (previously reported). Box displays 25% 1010 
and 75% percentiles with line showing median, and whiskers displaying minimum to maximum 1011 
values. Differences were considered significant when p-value <0.05 and calculated from Kruskal-1012 
Wallis test and Dunn’s multiple comparison test. HC: Healthy controls (n=60), PTBI: Pulmonary TB 1013 
infection (n=39) and ORD: Other respiratory diseases (n=22). HIV indicates HIV co-infection. HC-1014 
HIV (n=16), ATBI-HIV (n=53) and ORD-HIV (n=13)  1015 
 1016 
Fig. 9. Combination of four protein markers discriminates TB patients with HIV-coinfection 1017 
Receiver operator characteristic (ROC) curves were generated using SPSS v.25, for individual 1018 
proteins (CFHR5, LBP, SAA1and CRP) and after binary logistic regression for combined analytes.  1019 
ROC curve for TB infection vs. ORD in HIV uninfected individuals shows optimal performance from 1020 
the combined host panel, with AUC of 0.888 (A). Analysis of TB infection vs. ORD in HIV co-1021 
infected individuals produced an AUC of 0.976 from the combined panel (B). 1022 
 1023 
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Fig. 1. Overview of the plasma proteomic discovery and validation strategy of potential TB biomarkers.
(A) Identification and quantification of plasma proteins was performed using a quantitative multidimensional protein 
identification approach which comprises a series of fractionation steps at both protein (denaturing HP-SEC) and peptide level 
(offline high pH C4 HPLC followed by online low pH C18 UPLC). Initial plasma prefractionation using HP-SEC produces 5 
segments depending on the molecular size. Only segments 1 to 4 were included in this study since these include most of the 
protein contents. (B) Bioinformatic processing prioritised markers, which were then measured by ELISA or luminex in plasma 
or serum samples from two cohorts. Discovery and validation stages involved multiple ethnicities.
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Fig. 2. In-depth quantitative plasma proteome profiling in TB.
(A) Violin plots with median and interquartile range show molecular weight frequency distributions of proteins quantified 
(peptide confidence ≤1%FDR) in each independent HP-SEC segment. The number of proteins with relative quantitative data 
in all profiled samples is indicated. Four plasma samples from TB patients, three healthy controls and one master pool were 
analysed. (B) Abundance of quantified proteins from all HP-SEC segments. Only proteins with circulating levels reported in the
reference PaxDb1.4 protein abundance database or in the literature were annotated. Proteins considered as classical plasma 
proteins are indicated in red, tissue leakage proteins in green, proteins with signalling functions in purple and proteins 
associated to extracellular vesicles in yellow. Concentrations of detected proteins span 11 orders of magnitude. (C) Principal 
component analysis based on quantified proteins from all HP-SEC segments of eight profiled samples. iTRAQ tags and 
groups are indicated. Overall, TB patients were separated from healthy controls by the principal component PC1 and PC2, 
collectively explaining the 62% of total variance. The TB sample labelled with tag 121 clustered with the healthy control 
samples. The master pool, a combination of all samples, was located in the centre of the samples. (D) Log2 transformed 
relative protein expression heatmap of all proteins profiled in the four HP-SEC segments. Purple indicates TB patients and 
green healthy controls. Pearson correlation was used for clustering of proteins and Spearman for samples. Two clusters were 
defined based on the relative protein expression and GO analysis of these was performed using g:Profiler. Cyan: 
downregulated proteins; Magenta: upregulated proteins.
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Fig. 3. Detailed profiling of segment 4 identifies a differential plasma proteome in TB infection.
Analyses of common quantified proteins (peptide confidence FDR ≤ 0.01) derived from HP-SEC segment 4 across three 
iTRAQ experiments studying 10 controls and 11 TB patients (n = 426 proteins). (A) Volcano plot representation of plasma 
proteins differentially expressed in TB defined by LIMMA with FDR correction (q-value ≤0.05). Red indicates upregulated 
proteins and blue downregulated. Gene names of significantly regulated proteins with log2 fold change ≥|0.5| are shown. (B) 
WGCNA cluster dendrogram of quantified proteins into distinctive modules defined by dendogram branch cutting. Colour 
modules indicate protein clusters of highly interconnected proteins associated to the disease status. Correlation score and 
significance demonstrates that module turquoise is strongly correlated to TB status. (C) Gene ontology enrichment of proteins 
included in the module turquoise (n = 189). Dots represent the top 20 enriched cellular component organisation terms. Dot 
colour indicates significance (p-value Benjamini-Hochberg adjusted) and size represents the number of differential proteins in 
the significant gene list associated with the GO term. 
A2M
APOA1APOA2
APOD
BST1
C9
CD5L
CFB
CFH
CFHR5
CFP
CLU
CPN1
CRHBP
CRP
ECM1
HP
IGF1
IL1RAP
KNG1LBP
LYZ
ORM1
ORM2
PLA2G2A
PROC
PROS1
S100A12
S100A8
S100A9
SAA1
SAA2
SAA4
SERPINA1
SERPINA3
SERPINF1
SOD1
VTN
ACTB
AGA
ALB
APOC1
APOC2
APOC3
B2M
CD109
CDH13
CFD
CLEC3B
DLG4
DSC1
F9
FCGR3A
FCGR3B
FCN2
FGA
GGH
GM2A
HBB
HPX
ITIH3
LAMP2 LRG1
NPC2
PDCD6
PRG4
SELL
SERPINA4
SPP2TIMP2
TTR
MASP2
MZB1
RBP4
SPINK5
SUPT6H
GUCA2BTNFSF13B
PGLYRP2
ST6GAL1
APOA4
CST6
DAG1
FETUB
IHH
ITIH1
ITIH2
KLK6
MEP1A
MMP14
PEBP1
PIP
PSMB8
APOC4
APOM
SERPINA5
NENF
PTPRSTHBS4
Size
7
25
43
61
0
1
2
log2Fold change
Phospholipid transport
Lipid localization
Lipid transport
Organophosphate 
ester transport Acute-phase 
response
Acute inflammatory
response Humoral immune 
response
Inflammatory 
response
Regulation of response 
to external stimulus
Regulation of
inflammatory response
Negative regulation 
of hydrolase activity
Proteolysis
Regulation of production 
of molecular mediator 
of immune response
Immune effector 
process
Vesicle-mediated 
transport
Secretion
Exocytosis
Regulated exocytosis
Secretion by cell
Platelet 
degranulation
GSN
Fig. 4. Physiological changes in pulmonary TB are reflected in the plasma proteome.
Functional enrichment analysis of the biological processes was performed on the one hundred and eighty nine proteins 
strongly associated to the TB status and identified by WGCNA. Gene-concept network (c-net plot) depicts the linkages of 
proteins and the top 20 biological process terms enriched in the turquoise module. Up-regulated and down-regulated proteins 
were included. Green-to-red coding next to the network indicates the log2FC. Proteins in bold were selected for validation.
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Fig. 5. Top candidate biomarkers for active TB link to multiple biological processes.  
Chord plot for plasma proteins strongly correlated to active TB and identified by combining outputs from WGCNA and LIMMA. 
This plot links these proteins via ribbons to their associated biological processes. Blue-to-red coding next to the proteins 
indicates the log2FC. Gene ontology enrichment for biological process was performed in g:Profiler and only significant terms 
(FDR q-value ≤ 0.05) are shown. Plot generated with the R package GOplots.
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Fig. 6. Novel TB biomarkers validate in an independent UK cohort of mixed ethnicity.
Two novel TB biomarkers were significantly upregulated in TB infection measured by luminex or ELISA in serum from an 
independent UK-based cohort. (A) CFHR5 (Complement factor H related  protein 5) is increased in TB, and also significantly 
increased in other respiratory diseases (ORDs). Four known TB potential markers were measured and were significantly 
elevated in TB: (B) LRG1 (Leucine-rich alpha-2-glycoprotein). (C) LBP (Lipopolysaccharide binding protein), (D) SAA1 (Serum
amyloid A1), (E) CRP (C-reactive protein). (F) ILF2 (interleukin enhancer binding factor 2), a novel analyte from segment 3, 
was elevated in TB and ORDs. Box displays 25% and 75% percentiles with line showing median, and whiskers displaying 
minimum to maximum values. Differences were considered significant when p-value <0.05 and calculated from Kruskal-Wallis 
test and Dunn’s multiple comparison test. HC: Healthy controls (n = 30), LTBI: Latent TB infection (n = 30), PTBI: Pulmonary 
TB infection (n = 32) and OR: Other respiratory diseases (n = 26). 
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Fig. 7. Combination of five protein markers discriminates TB patients in a UK-based cohort
Receiver operator characteristic (ROC) curves were generated using SPSS v.25, for individual proteins (CFHR5, LBP, SAA, 
CRP and ILF2) and after binary logistic regression for combined analytes. AUC was estimated under nonparametric 
assumption. TB was set as the positive test outcome and the test direction such that larger test result indicates a more positive
test. ROC curve for TB infection vs. healthy controls shows good discrimination, with the multiplex panel most discriminatory 
(A), while the ROC curve for TB infection vs. ORD shows individual analytes are not differentiating, but a combined multiplex 
generates an AUC of 0.813 (B).
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Fig. 8. CFHR5 validates as a new diagnostic marker of TB in HIV-coinfection, and multiplex analysis performs well 
against other respiratory conditions.
(A) CFHR5 was significantly upregulated during active TB infection in a previously reported South African cohort, in both HIV 
uninfected and HIV infected individuals. Three other potential TB markers were also elevated: (B) LBP, (C) SAA1 and CRP 
(previously reported). Box displays 25% and 75% percentiles with line showing median, and whiskers displaying minimum to 
maximum values. Differences were considered significant when p-value <0.05 and calculated from Kruskal-Wallis test and 
Dunn’s multiple comparison test. HC: Healthy controls (n = 60), PTBI: Pulmonary TB infection (n = 39) and ORD: Other 
respiratory diseases (n = 22). HIV indicates HIV co-infection. HC-HIV (n = 16), ATBI-HIV (n = 53) and ORD-HIV (n = 13) 
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Fig. 9. Combination of four protein markers discriminates TB patients with HIV-coinfection 
Receiver operator characteristic (ROC) curves were generated using SPSS v.25, for individual proteins (CFHR5, LBP, SAA1
and CRP) and after binary logistic regression for combined analytes.  ROC curve for TB infection vs. ORD in HIV uninfected 
individuals shows optimal performance from the combined host panel, with AUC of 0.888 (A). Analysis of TB infection vs. 
ORD in HIV co-infected individuals produced an AUC of 0.976 from the combined panel (B).
